© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
Uptake of new heart failure drugs slow despite guidelines
EXPERT ANALYSIS FROM THE CARDIOVASCULAR CONFERENCE AT SNOWMASS
Related Articles
Catheter Ablation Versus Antiarrhythmic Drug Therapy for Ventricular Tachycardia
April 5, 2017
CLINICAL QUESTION: Among patients with ischemic cardiomyopathy and ventricular tachycardia, is catheter ablation or antiarrhythmic drug therapy a more effective initial strategy BACKGROUND:...
Monoclonal Antibody Abelacimab Compared to Rivaroxaban Had Lower Rates of Bleeding Complications
April 5, 2017
CLINICAL QUESTION: Can the inhibition of free factor XI with a monoclonal antibody be used for stroke prevention in Atrial fibrillation patients? BACKGROUND: Atrial fibrillation is a common...
Comparing Efficacy and Safety Between Patients with AF Taking DOACs or Warfarin After a DOAC Failure
April 5, 2017
CLINICAL QUESTION: Is warfarin better as a second-line anticoagulant than another direct oral anticoagulant (DOAC) in patients with atrial-fibrillation-induced ischemic strokes after failure of a...
Beta-Blockers Didn’t Reduce Mortality After Acute MI in Patients with Preserved Ejection Fraction
April 5, 2017
CLINICAL QUESTION: Do beta-blockers still reduce mortality after acute myocardial infarction (MI) in the modern era of faster and better reperfusion strategies? BACKGROUND: Beta-blockers have...